Cutting administrative overhead by using universal prior authorization systems for multi-state health plans;

Maintaining FDA oversight of the safety and effectiveness of biosimilars “to encourage market-based relief from the high costs of biologic drugs”

The ACR letter comes just weeks after a similar one from the American Medical Association.


“In considering opportunities to make coverage more affordable and accessible to all Americans,” wrote AMA CEO Dr. James L. Madara to House and Senate leaders, “it is essential that gains in the number of Americans with health insurance coverage be maintained.”

The letter then went on to state that, “Consistent with this core principle, we believe that before any action is taken through reconciliation or other means that would potentially alter coverage, policymakers should lay out for the American people, in reasonable detail, what will replace current policies. Patients and other stakeholders should be able to clearly compare current policy to new proposals so they can make informed decisions about whether it represents a step forward in the ongoing process of health reform.”

Back to HCB News

U.S. Healthcare Homepage